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Abstract
The control of infectious diseases is a major current challenge in intensive aquaculture.
Most commercial vaccines are based on live attenuated or inactivated pathogens that
are usually combined with adjuvants, oil emulsions being as the most widely used for vacci-
nation in aquaculture. Although effective, the use of these oil emulsions is plagued with
important side effects. Thus, the development of alternative safer and cost-effective immu-
nostimulants and adjuvants is highly desirable. Here we have explored the capacity of inclu-
sion bodies produced in bacteria to immunostimulate and protect fish against bacterial
infections. Bacterial inclusion bodies are highly stable, non-toxic protein-based biomaterials
produced through fully scalable and low-cost bio-production processes. The present study
shows that the composition and structured organization of inclusion body components (pro-
tein, lipopolysaccharide, peptidoglycan, DNA and RNA) make these protein biomaterials
excellent immunomodulators able to generically protect fish against otherwise lethal bacte-
rial challenges. The results obtained in this work provide evidence that their inherent nature
makes bacterial inclusion bodies exceptionally attractive as immunostimulants and this
opens the door to the future exploration of this biomaterial as an alternative adjuvant for
vaccination purposes in veterinary.
Introduction
The industrialization of fish production has raised numerous issues related to intensive exploi-
tation. One of the most important challenges is the control of infectious diseases, which are eas-
ily transmitted under high-density rearing conditions, leading to significant economic losses
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[1, 2]. Currently available commercial vaccines are made of live attenuated or inactivated path-
ogens [1, 3]. However, vaccines based on live attenuated bacteria are not widely used for safety
reasons, while the existing vaccines based on inactivated pathogens are generally weakly immu-
nogenic. This limitation associated with inactivated vaccines is frequently overcome by the co-
administration of immunostimulants or adjuvants [4] that are most widely applied as oil emul-
sions [5]. Even so, the use of oil emulsions to get a successful prophylaxis has important side
effects. In this context, many other potential immunostimulants are being studied, including
immune stimulating complexes (ISCOMs), beta-glucans, poly (I:C), lipopeptidases, lipopoly-
saccharide (LPS), flagellin, CpG and cytokines. Although some of these show promising fea-
tures, in general terms, the obtained results vary considerably. For example, the protective
effect of LPS against fish diseases has been frequently proven in vivo after challenge with cer-
tain bacterial pathogens [6–8], but not with others [9, 10]. This could be partially explained by
the origin and purity of the LPS used [11]. Additionally, Mackenzie et al. (2010) concluded
that variations in the amount of contaminants such as peptidoglycan (PGN) and nucleic acids
clearly determine the extent of stimulation by the different LPS samples tested. Interestingly,
they point out that an enhancement of the immune response after using LPS as an immuno-
modulator is the result of the effect of the complex mixture in crude LPS [9]. Moreover, it has
been proven that non-protective doses of LPS, when combined with poly (I:C), exert a clear
protection against Pseudomonas aeruginosa when encapsulated in nanoliposomes [12]. Thus,
considering that a combination of immunostimulants has a powerful effect and that it would
be highly convenient to develop a general immunostimulant able to release the active molecule
slowly at lower doses, bacterial inclusion bodies (IBs) appear to be a promising alternative.
IBs are mechanically stable, non-toxic protein-based particulate biomaterials produced in
recombinant Escherichia coli cells under overexpressing conditions [13]. This biomaterial is
mainly composed of recombinant heterologous protein, but it also contains different bacterial
components such as membrane remnants, membrane bound proteins, nucleic acids, cell wall
fragments and, consequently, LPS and PGN [14–16]. Noteworthy, these elements have been
proven to act as strong stimulants of the fish immune system [10]. In addition, IBs show other
important characteristics that make them an appealing potential immunostimulant. On the
one hand, they are produced through fully scalable, simple and cost-effective biofabrication
processes. On the other hand, they have been shown to be highly stable over time under differ-
ent conditions and, importantly, many physicochemical parameters of the material are fully
adjustable by both genetic and process engineering [17]. Thus, all these aspects make this bio-
material a highly versatile option with excellent potential to be used as a generic immunostimu-
lant to improve vaccination effectiveness in fish against a wide range of infectious diseases.
In this study, we have explored and characterized IBs as a new immunostimulant for fish.
Data presented here indicate that bacterial IBs formed by non-biologically active heterologous
proteins (VP1GFP and iRFP) are excellent modulators of host defences able to protect fish
against bacterial infections.
Materials and Methods
Bacterial strains and plasmids
The bacterial strains used in this work to produce IBs included the E. coli K-12 derivative JGT4
(ClpA-; clpA::kan, araD139 (argF-lac) U169 rpsL150 relA1 flbB5301deoC1 ptsF25 RbsR, SmR)
[18], referred to as ClpA-, and the endotoxin-free E. coli K-12 strain KPM335 (msbA52,ΔgutQ,
ΔkdsD, ΔlpxL, ΔlpxM, ΔpagP, ΔlpxP, ΔeptA, frr181) [19]. These strains were transformed with
the pTVP1GFP (ApR) plasmid (GenBank acc. number KM242650) for the production of
VP1GFP IBs. VP1GFP is a modular protein consisting of the green fluorescent protein (GFP)
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fused to the VP1 protein of the capsid of the foot-and-mouth disease virus. In addition, E. coli
BL21 (DE3) cells (F−ompT hsdSB(rB−mB–) gal dcm lon λ(DE3 [lacI lacUV5-T7 gene 1 ind1
sam7 nin5]) (Novagen) were transformed with pET22b-iRFP-H6 (ApR) for the production of
iRFP-H6 IBs. iRFP-H6 is an infrared fluorescent protein fused to a His-tag.
Production and purification of IBs
E. coli strains carrying the protein expression plasmids were cultured in LB medium supple-
mented with ampicillin (100 μg/ml). Bacterial cultures were started at an optical density at 550
nm (OD550) of 0.05 and incubated aerobically (250 rpm) at 37°C until they reached an OD550
of 0.5. Then, 1 mM isopropyl-D-thiogalactoside (IPTG) was added and protein expression was
induced for 3 h. For purification of IBs, the bacterial cultures were processed through a combi-
nation of enzymatic and mechanical disruption steps. First, lysozyme (1 μg/ml) and phenyl-
methanesulfonyl fluoride (PMSF, 0.4 mM) were added to cell cultures and incubated at 37°C
for 2 h and 250 rpm. Then, the cells were frozen and thawed, followed by addition of Triton X-
100 (0.2% (v/v)) and incubation at room temperature (RT) for 1 h with gentle agitation. IBs
were harvested by centrifugation and resuspended in PBS using one tenth of the original cul-
ture volume. Next, samples were treated with 0.6 μg/ml DNase at 37°C for 1 h under agitation.
Freeze/thaw cycles were repeated until no viable bacteria were detected. For this, 100 μl of the
culture was seeded in LB plates without antibiotic and cultivated overnight at 37°C. Samples
were centrifuged at 15,000 x g for 15 min, and pellets containing purified IBs were stored at
-80°C until use. Finally, bacteria viability was assessed incubating purified IBs in DMEMwith
10% of FBS without antibiotic during 5 days at 37°C. IBs were semiquantified by Western Blot
densitometry (ImageJ) using anti-GFP and anti-RFP antibodies (Santa Cruz), and protein con-
centrations were inferred from standard curvesmade with GFP and iRFP soluble recombinant
proteins that have been deeply characterized in our group.
Structural characterization of IBs
VP1GFP IBs produced in ClpA- (VP1GFP (ClpA-)), VP1GFP IBs produced in KPM335
(VP1GFP (KPM335)) and iRFP-H6 IBs produced in BL21(DE3) (iRFP-H6 (BL21(DE3)) were
resuspended in deionizedwater at a final concentration of 1 μg/ml (quantification done by
Western blot). Twenty microliters of these suspensions were incubated on silicon chips at RT
for 2 min. After incubation, excess water was removed and the samples were air-dried over-
night prior to Field Emission Scanning ElectronMicroscopy (FESEM, ZeissMerlin) observa-
tion. FESEM images were processed using the image analysis software ImageJ. Diameter
measurements of at least 105 particles per sample were carried out, and size distribution graphs
were generated using Past3 software.
Cell cultures
The zebrafish liver ZFL cells (CRL-2643, ATCC) were cultured at 28°C in a humidified atmo-
sphere with 5% CO2 in Dulbecco´smodifiedEagle´smedium (DMEM) containing 4.5 g/l glu-
cose, 0.01 mg/ml insulin, 50 ng/ml epidermal growth factor (EGF), 5% (v/v) of antibiotic/
antimycotic, 10% (v/v) heat inactivated fetal bovine serum (FBS) and 0.5% (v/v) heat-inacti-
vated rainbow trout serum (TS) [12]. The rainbow trout macrophages (RT-HKM) were
obtained from head kidney as describedpreviously [20] and cultured in DMEMwith 4.5 g/l
glucose, 10% (v/v) heat inactivated FBS and 50 μg/ml Primocin (Invivogen) at 16°C and 5%
CO2. Fully differentiatedmacrophages (day 5) were used for IB uptake and gene expression
experiments.
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VP1GFP (ClpA-) IB uptake by zebrafish liver cells (ZFL) and rainbow
trout macrophages (RT-HKM)
The uptake of VP1GFP (ClpA-) IBs by both zebrafish liver cells (ZFL) and rainbow trout macro-
phages (RT-HKM) was analyzed by flow cytometry and confocalmicroscopy. For the dose-
response uptake assays, the ZFL and RT-HKM cells were seeded in 24-well plates and incubated
with protein particles (IBs) at different doses (2, 4, 10 and 40 μg/ml) of VP1GFP (ClpA-) for 24 h
(n = 4). For the time-course uptake assays, cells were treated with 20 μg/ml of VP1GFP (ClpA-)
IBs and samples were taken at indicated times (ZFL: 2, 4, 8, 16 and 24 h post-treatment;
RT-HKM: 0.5, 1, 2, 4, 8 and 24 h post-treatment; n = 4). After incubation, the mediumwas dis-
carded, and the cells were rinsedwith PBS to remove FBS. Each sample was treated with 1 mg/ml
trypsin (Gibco) for 15 min to detach cells and remove externally attached IBs [21] and then centri-
fuged at 300 x g for 5 min, pellets were resuspended in 200 μl of PBS. The IBs uptake was analyzed
using a FACS-Canto instrument (BectonDickinson,USA) with a 15 mW air-cooled argon ion
laser at 488 nm (GFP fluorescence excitation) and a D detector (530/30 nm band pass filter) for
the detection of fluorescence emission. Both dose and time-course experimentswere repeated four
times, collecting 10,000 events for each sample. The results were analyzed with one-way ANOVA
and a Tukey`s post-test. For confocalmicroscopy, the ZFL and RT-HKM cells were seeded in indi-
vidual plates at 60% confluency and incubatedwith 20 μg/ml VP1GFP (ClpA-) for 24 h at 28 C for
ZFL and 16°C for HKM.After three PBS washes, the nuclei and membranes were labeledwith
Hoechst and CellMask, respectively. The samples were examinedwith a Zeiss LSM 700 micro-
scope (Germany), and image analysis was performedwith Imaris (Bitplane AG, Switzerland).
Cell toxicity assay
Sub confluent ZFL cells cultured in 96 well plates were incubated with 0.1, 1 and 10 μg per well
of bacterial VP1GFP (ClpA-) IBs for 24 h at regular cell culture conditions, as describedbefore
in Cell cultures methodology. After incubation cell viability was assessed throughMTT assay
using the EZ4U kit (Biomedica, GmbH, Austria) followingmanufacturer’s specifications.
Gene expression analysis
The effects of iRFP-H6 (BL21(DE3)) and LPS (LPS from E. coli 0111:B4, purified by phenol
extraction. REF: L2630, SIGMA) on RT-HKM gene expression were analyzed by quantitative
real-time PCR (qPCR). It is important to note that we decided to use trout macrophage pri-
mary cultures because the small size of the zebrafish did not allow obtaining enough cells for
the qPCR analysis. The RT-HKM cells were seeded in 6-well plates at 80% confluency. Cells
were incubated with 10 μg/ml of iRFP-H6 (BL21(DE3)) IBs or 10 μg/ml LPS for 12 h at 16°C
(n = 3). Total RNA was extracted using TriReagent following the manufacturer’s instructions
(Sigma). The concentration and quality of the RNA samples were evaluated using a Nanodrop
ND-1000 spectrophotometer (Thermo Scientific,USA) and the Bioanalyser-2100 with the
RNA 6000 Nano Kit (Agilent Technologies), respectively. The cDNA synthesis was performed
with 1 μg of total RNA using SuperScript III reverse transcriptase (Invitrogen) and oligo-dT15
primer (Promega). The qPCR was carried out using SYBR Green I PCR Supermix (Bio-Rad),
250 nM of primers (Table 1) and 2.5 μl of diluted cDNA (1:50 for target mRNA and 1:500 for
reference gene) in a final volume of 10 μl. The primers used in the present study are listed in
Table 1. The gene for elongation factor 1 alpha (EF1) was used as a reference, and quantifica-
tion was done according to the Livak method [22]. The experiment was repeated three times,
and all samples were analyzed in triplicate by qPCR. The results were analyzed using One-way
ANOVA followed by Tukey’s post test.
Biomaterials as Immunostimulants
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HEK-Blue LPS detection
The LPS detection assays using tenfold serial dilutions of VP1GFP (ClpA-), VP1GFP
(KPM335) and iRFPH6 (BL21(DE3)) IBs were performed by triplicate with HEK-Blue™ hTLR4
cells in accordance with the specifications of the supplier (InvivoGen). Stimulation of these
cells induces the production of the NF-κB -and activator protein-1 (AP-1)-dependent reporter
secreted embryonic alkaline phosphatase (SEAP). NF-κB-dependent SEAP activity was deter-
mined by reading the absorbance at 655 nm following incubation of the samples at 37°C for 3
h in the presence of the QUANTI-Blue™ substrate. For the positive control experiments, tenfold
serial dilutions of LPS from E. coli K-12 (InvivoGen) and recombinant human TNF-α (200 ng/
well) (InvivoGen) were used. To determine the basal levels of SEAP (NF-κB) activity, pyrogen-
free water and Dulbecco´sphosphate-buffered saline served as negative control. The positive
and negative control reactions were prepared with the same number of HEK-Blue cells per well
and assayed under the same conditions as for the IBs.
HEK-Blue™ Null2 cells, the parental cell line of HEK™-Blue hTLR4 cells lacking the hTLR4/
MD-2 receptor complex, were used as a control in all hTLR4/MD-2 activation assays.
Total lipid content
The total lipid content of the IBs was analyzed following the procedure described by Izard
et al [23]. Briefly, 1 mg of IBs was lyophilized and 200 μl of chloroform were added and let to
evaporate. The samples were subsequently resuspended in 100 μl of deionized water. Two
milliliters of 18 M sulphuric acid were added, followed by an incubation of the samples in a
boiling water bath for 10 min. As soon as the samples were cooled down, 5 ml of phosphoric
acid—vanillin (0.12 g vanillin in 100 ml of 85% acid) were added and incubated at 37°C for
15 min. The absorbance was measured at 530 nm, and samples were quantified by inferring
the total lipid amount out from a triolein standard curve. All assays were performed in
triplicate.
Animals
Adult wild-type zebrafish (Danio rerio) were maintained in a recirculation freshwater system
under a photoperiod of 12:12 h light/dark cycle at 28 ± 0.5°C and fed daily with a commercial
Table 1. Rainbow trout specific primers for qPCR.
Gene Primer name Sequence Accession n˚
Elongation factor 1 α om_EF-1 For_CAAGGATATCCGTCGTGGCA NM_001124339.1
Rev_ACAGCGAAACGACCAAGAGG
Tumor necrosis factor α om_TNF-α For_CGCTGACACAGTGCAGTGGA NM_001124357.1
Rev_TCCCCGATGGAGTCCGAATA
Interleukin 1 β om_IL-1β For_GGAGGCAGCAGCTACCACAAA NM_001124347.2
Rev_CCGATTTGGAGCAGGACAGG
Interleukin 8 om_IL-8 For_AGAATGTCAGCCAGCCTTGT AJ279069
Rev_TCTCAGACTCATCCCCTCAGT
Cyclooxygenase 2 om_COX-2 For_TACCAAGCAGATCGCTGGAC NM_001124348.1
Rev_GCGTATGGCTTCATGGAGAA
Matrix metalloproteinase 9 om_MMP9 For_TTCCAATTCAAGGGCAACTC NM_001124370.1
Rev_TCAGCCCCCACAGTTAAGAG
Suppressor of cytokine om_SOCS3 For_AACAACACAAGATATCAAGCTCAAG AM748723.1
signaling 3 Rev_GAAGGTCTTGTAACGGTGAGGCAG
doi:10.1371/journal.pone.0164073.t001
Biomaterials as Immunostimulants
PLOS ONE | DOI:10.1371/journal.pone.0164073 October 7, 2016 5 / 17
diet. All experimental procedures were approved by the Ethical Committee of the Universitat
Autònoma de Barcelona (Reference number 1968 and HR-14-13) according to the Interna-
tional Guiding Principles for Biomedical Research Involving Animals (EU 2010/63). The infec-
tion procedure includedmonitoring of humane endpoints (numerical scale from 0 to 4) that
requires euthanization of the animals when they show signs of infection (ethyl 3-aminobenzo-
ate methanesulfonate, MS222 overdose of 300 ppm). We evaluate the clinical symptoms of
infection as follow 0. Normal; 1. abdominal distension; 3. Loss of scales; 4. Abdominal or gill
bleeding and the behavioural symptoms as 0. Normal; 1. Erratic or horizontal swimming; 2.
Swimming just below the surface; 3. Sink to the bottom of the tank; 4. No touch response.
When the sum of the clinical symptoms and the behavioural symptoms is between 1–3 we
supervise the fish every 3 h during the day (instead of twice a day) and when it is more than 3
we euthanize the animal (MS222 overdose) and we compute it as a death.
In vivo treatment of Zebrafish with VP1GFP (ClpA-), VP1GFP (KPM335)
and iRFP-H6 (BL21(DE3)) IBs
Zebrafish (0.53 ± 0.07 g body weight) were placed into small tanks (4 L) at 28 ± 1°C 1 day
before the experiments. Pseudomonas aeruginosa (PAO1, sub-line MPAO1; obtained from
the Seattle PAO1 transposonmutant library, University of Washington) was cultured as
described previously [12]. First, we evaluated a dose-response of VP1GFP (ClpA-) (300, 150,
75, 50 and 25 μg/ml), then, we compared the protection betweenVP1GFP (ClpA-) and
VP1GFP (KMP335) (300 μg/ml), and finally, betweenVP1GFP (ClpA-) and iRFP-H6 (BL21
(DE3)) (150 μg/ml) (n = 15). For IBs and PAO1 injection, the fish were anaesthetized with
MS-222 (166 ppm) and intraperitoneally (i.p) injected with either 20 μl of IBs or PBS as a
control. At 7 days post-injection, the fishes were challenged by i.p. injection with 20 μl of
P. aeruginosa PAO1 (LD50 = 6.5 x 107 cfu/animal) and their survival was followed for 7 days.
Survival curves were analyzed using the Kaplan–Meier method and the statistical differences
were evaluated using the log-rank test (GraphPad, USA). Relative percentage of survival
(RPS) was calculated according to RPS (%) = [(1 − mortality treated group)/mortality con-
trol] × 100.
Results
Purification and characterization of IBs
Bacterial IBs were successfully produced in E. coli and purified by a combination of mechanical
and enzymatic methods. As shown in Fig 1A, the appearance of the particles differs depending
on the protein and the bacterial strain used as a producer. The iRFP-H6 IBs appeared as spheri-
cal particles, whereas VP1GFP IBs exhibited, particularly in the case of those produced in
KPM335, quite irregular shapes. With regard to size distributions, the IBs turned out to be
polydisperse particles ranging from 100 nm to 800 nm in diameter. Nevertheless, a main peak
could be clearly observedplaced between 300–400 nm, 400–500 nm and 500–600 nm in diam-
eter for the VP1GFP (KPM335), VP1GFP (ClpA-) and iRFP-H6 (BL21(DE3)) IBs, respectively
(Fig 1A).
Moreover, a detailed inspection of the SEM images revealed differences in the amount of
IB-associated cellular debris, which most likely is a remnant of bacterial cell membranes. Parti-
cles produced in the ClpA-defective E. coli strain showed higher amounts of cell debris co-puri-
fied with the protein particles (Fig 1A). This observationwas in accordance with the values
obtained for total lipid quantification of purified IBs, with VP1GFP (ClpA-) IBs showing the
highest lipid/protein ratio (Fig 2A).
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Uptake of VP1GFP (ClpA-) IBs by zebrafish liver cells (ZFL) and
rainbow trout macrophages (RT-HKM)
One of the main properties of IBs is their ability to cross mammalian cell membranes [21, 24].
To explore the interaction of IBs with fish cells, the uptake of VP1GFP (ClpA-) IBs by zebrafish
liver cells (ZFL) was assessed. The results showed that ZFL cells were able to uptake VP1GFP
(ClpA-) IBs (Fig 3). The dose-response assays analyzed by flow cytometry indicated that
VP1GFP (ClpA-) IBs tested were clearly endocyted by ZFL cells at all concentrations
(14 ± 1.35% positive cells at 2 μg/ml and 35 ± 4.9% positive cells at 40 μg/ml) (Fig 3A). Addi-
tionally, IBs did not cause significant toxicity in these cells (S1 Fig), as it has been previously
described for mammalian cell lines such as, HeLa, HL-60 and NIH-3T3 [24, 25]. The time-
course indicated that the VP1GFP (ClpA-) IBs started to be endocyted by ZFL cells quite rap-
idly (10 ± 1.87% positive cells at 2 h post exposure), and after 24 h half of the cells contained
internalized IBs (48 ± 5.9% at 24 h) (Fig 3B). To explore the interaction of IBs with professional
phagocytes such as macrophages, we assessed the uptake of VP1GFP (ClpA-) IBs by rainbow
trout macrophages (RT-HKM) (Fig 4). The results showed that trout macrophages were able
Fig 1. Characterization of IB particles. A) FESEM images and B) size distribution of VP1GFP (ClpA-), VP1GFP
(KPM335) and iRFP-H6 (BL21(DE3)) IBs.
doi:10.1371/journal.pone.0164073.g001
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to uptake VP1GFP (ClpA-) IBs even more efficiently than ZFL cells since, at 40 μg/ml, around
70% of trout macrophages were positive for IB uptake (72.17 ± 3.08%) (Fig 4A). A linear corre-
lation between dose and uptake is observed in both ZFL and RT-HKM cells with a R2 = 0.8477
and R2 = 0.9993, respectively. We also observed that VP1GFP (ClpA-) IB started to be endo-
cyted by RT-HKM cells faster than by ZFL cells (30.3 ± 6.99% at 0.5 h), and 24 h after exposure
about 80% of the cells were positive (78.67 ± 2.23% at 24 h) (Fig 4B). Interestingly, a clear linear
correlation exists between time and internalization values in the time-course experiment per-
formed with ZFL cells (R2 = 0.9261) However, RT-HKM time-course fits an hyperbolic correla-
tion (R2 = 0.8994). Confocalmicroscopy and 3D-reconstruction images enabled the
visualization of VP1GFP (ClpA-)-agglomerates in the cytosol of ZFL and RT-HKM cells (Figs
3C and 4C). These images demonstrated the complete internalization of IBs by both cell lines
(Figs 3C (iii) and 4C (ii and iv)).
Immunization of zebrafish with VP1GFP IBs produced in E. coli strains
with different LPS chemotypes
Next, to evaluate whether IBs were able to confer protection against a lethal infection in vivo,
we used a zebrafish bacterial infectionmodel with P. aeruginosa as an infectious agent [12].
The results showed higher survival rates when zebrafish were treated with different doses of
VP1GFP (ClpA-) IBs, being significantly higher at 300, 150 and 75 μg (RPS of 76% at 300 μg,
79% at 150 μg and 67% at 75 μg) (Fig 5). Importantly, we did not observe any secondary effect
after IB injection and animal behavior was normal after that.
After having established the optimal dose of VP1GFP (ClpA-) that confer protection and
since our working hypothesis was to use IBs as a general immunostimulant, we decided to ana-
lyze the specific role of LPS normally present in IBs in the observedeffect. For that purpose, we
compared the effects on fish survival of VP1GFP IBs produced in E. coli ClpA- and E. coli
KPM335. The latter strain has been demonstrated to synthesize lipid IVA as the only LPS-related
molecule, which lacks endotoxic activity in human LPS-responsive cells [19]. HEK-blue assay
results showed that, IBs produced in KPM335 were unable to activate the hTLR4/MD-2 signaling
Fig 2. Lipid quantification and dose-response curves of NF-κB induction by IBs. A) Total lipid quantification of IB samples. Differences were analyzed
using the T test, *, p<0.01. The IBs produced in E. coli strains with different LPS chemotypes were assayed with HEK™-Blue hTLR4 (B) and Null2 (C) cells
for relative NF-κB induction. The absorbance values despicted in Fig 2B and 2C represent the means and standard deviations from three individual
experiments. The IBs displayed negligible stimulation of the parental HEK™-Blue Null2 cell line (C), which indicates that NF-κB-dependent SEAP
expression was specifically induced via the hTLR4/MD-2 signalling pathway in HEK™-Blue hTLR4 cells.
doi:10.1371/journal.pone.0164073.g002
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pathway in the HEK-Blue assay (Fig 2B). In contrast, the stimulation of the HEK-Blue cell line
was high when standard E. coli K-12 and B strains containing endotoxically active LPS were used
Fig 3. Uptake of VP1GFP (ClpA-) IBs by ZFL cells. A) Dose-response. Cells were incubated with 2 to 40 μg/ml of VP1GFP (ClpA-) IBs for 24
h. Values represent the mean and SD (n = 4). Differences were analyzed using One-way ANOVA and Tukey’s post test. Significant differences
against control: ***, p<0.0001. B) Time-course. Cells were incubated with 20 μg/ml of VP1GFP (ClpA-) IBs for 2, 4, 8, 16 and 24 h. Values
represent the mean and SD (n = 4). Differences were analyzed using One-way ANOVA and Tukey’s post test. Significant differences against
control: ***, p<0.0001. C) Confocal microscopy images of VP1GFP (ClpA-) IB uptake by ZFL cells (green). Cells were incubated 24 h with
20 μg/ml of VP1GFP (ClpA-) IBs. CellMask (red) was used for plasma membrane staining and Hoechst (blue) for nuclei labeling. i. Control cells.
ii. ZFL cells at 24 h post-incubation with VP1GFP (ClpA-) IBs. iii. 3D image reconstruction of VP1GFP (ClpA-) IBs uptake by ZFL cells (z-stack).
doi:10.1371/journal.pone.0164073.g003
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Fig 4. Uptake of VP1GFP (ClpA-) IBs by RT-HKM cells. A) Dose-response. Cells were incubated with 2 to 40 μg/ml of VP1GFP (ClpA-) for 24 h.
Values represent the mean and SD (n = 4). Differences were analyzed using One-way ANOVA and Tukey’s post tests. Significant differences against
control: *, p<0.05; ***, p<0.0001. B) Time-course. Cells were incubated with 20 μg/ml of VP1GFP (ClpA-) for 0.5, 1, 2, 4, 8 and 24 h. Values represent
the mean and SD (n = 4). Differences were analyzed using One-way ANOVA and Tukey’s post test. Significant differences respect control: ***,
p<0.0001. C) Confocal microscopy images of VP1GFP (ClpA-) IB uptake by RT-HKM cells (green). Cells were incubated 24 h with 20 μg/ml of
VP1GFP (ClpA-). CellMask (red) was used for plasma membrane staining and Hoechst (blue) for nuclei labeling. i. Control cells. ii. RT-HKM cells at 24
h post stimulation with VP1GFP (ClpA-) IBs. iii. 3D image reconstruction of VP1GFP (ClpA-) uptake by RT-HKM cells. iv. 3D image reconstruction of
VP1GFP (ClpA-) uptake by RT-HKM cells (z-stack).
doi:10.1371/journal.pone.0164073.g004
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(Fig 2B). Despite this difference in the endotoxic activity, the survival rate of fish immunized
with IBs produced in the LPS-free strain (VP1GFP (KPM335)), achieving an RPS of 75%, was
significantly higher than the control. However, no significant differences between survival rates
associatedwith VP1GFP (ClpA-) IBs and VP1GFP (KPM335) IBs were observed (Fig 6).
As we have mentioned above, we also tested the total lipid content of the IBs produced in
the different E. coli strains used (Fig 2A). The presence of total lipids were reduced in KPM335
(140 μg/μg lipid/protein ratio) compared to ClpA- (320 μg/μg lipid/protein ratio) (Fig 2A).
Fig 5. Immunization of zebrafish with VP1GFP (ClpA-) IBs. Survival curves of zebrafish after i.p. injection of
VP1GFP (ClpA-) IBs at different doses (300, 150, 75, 50 and 25 μg/fish) and challenge with P. aeruginosa PAO1
(4.3x107 cfu/animal) (n = 13). Untreated zebrafish that had been infected with PAO1 at LD50 were used as a
mortality control. Significant differences were analyzed using the Log-rank test; **, p<0.01; *, p<0.05.
doi:10.1371/journal.pone.0164073.g005
Fig 6. Immunization of zebrafish with VP1GFP (ClpA-) and VP1GFP (KPM335) IBs. Survival curves of zebrafish
after i.p. injection of VP1GFP (ClpA-) and VP1GFP (KPM335) (300 μg/fish) and challenge with P. aeruginosa PAO1
(3.4x107 cfu/animal) (n = 15). Untreated zebrafish that had been infected with PAO1 at LD50 were used as a mortality
control. Significant differences were analyzed using the Log-rank test; **, p<0.01.
doi:10.1371/journal.pone.0164073.g006
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Immunization with VP1GFP (ClpA-) and iRFP-H6 (BL21(DE3)) IBs
In order to examine whether the amino acid sequence of the protein forming the IBs may con-
tribute to zebrafish protection upon challenge, VP1GFP (ClpA-) and iRFP-H6 (BL21(DE3))
IBs were compared. Our results showed that both the VP1GFP (ClpA-) and the iRFP-H6
(BL21(DE3)) IBs developed comparable protection levels (RPS of 55% and 72.5%, respectively)
after a lethal challenge with P. aeruginosa PAO1 (Fig 7).
Gene expression of immune response genes in rainbow trout
macrophages (RT-HKM)
To explore the ability of the IBs to stimulate the expression of immune-related genes in specific
immune cells, we treated RT-HKM cells with iRFP-H6 (BL21) IBs and with LPS (dose with
proven pro-inflammatory activity in trout macrophages model) as a control [20]. In general,
we observed a similar increase of the gene expression in iRFP-H6 (BL21) IBs- and LPS-treated
macrophages (Fig 8). The pro-inflammatory cytokines TNF-α, COX-2, IL-1β and IL-8 reached
almost the same expression levels with iRFP-H6 (BL21) IBs and LPS-stimulated cells (Fig 8).
As shown in Fig 8, their expression levels also increased in iRFP-H6 IBs-treatedmacrophages
(11.9 ± 4.9 fold change for MMP9 and 14.88 ± 6.94 fold change for SOCS3), but they did not
reach the same expression levels as in the LPS-treated cells (around 50% higher).
Discussion
The development of new and effective vaccines is an increasing need for intensive aquaculture
to prevent and control major diseases [2, 3]. So far, vaccines based on inactivated pathogens
have been the most widely used approach to prevent important diseases. However, this strategy
is inefficient in many cases, frequently requiring of high doses and/or the co-administration of
adjuvant molecules to achieve the desired protection [1]. Thus, aiming to develop effective and
cost-effective prophylaxis methods, future vaccine research is focused on both the improve-
ment of vaccine potency and efficacy and the use of molecules with a general immunostimula-
tory profile. On the latter point, although several adjuvants have been explored, most of them
Fig 7. Immunization of zebrafish with VP1GFP (ClpA-) and iRFP-H6 (BL21(DE3)) IBs. Survival curves after i.p. injection
of VP1GFP (ClpA-) and iRFP-H6 (BL21(DE3)) IBs at 150 μg/fish and challenge with P. aeruginosa PAO1 (4.9x107 cfu/
animal) (n = 15). Untreated zebrafish that had been infected with PAO1 at LD50 were used as a mortality control. Significant
differences were analyzed using the Log-rank test, **, p<0.01.
doi:10.1371/journal.pone.0164073.g007
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show adverse side effects and/or do not show consistent levels of protection [26]. In this con-
text, the results of this study show that bacterial IBs can be used as an alternative broad-spec-
trum immunostimulant-delivery platform for fish. IBs are complex, mechanically stable and
functional biomaterials that combine several key properties attractive in their use as immunos-
timulants. Although their main component is the recombinant protein, they also contain unde-
termined amounts of other molecules of the bacterial production strain such as bacterial DNA,
RNA and cell wall components, including LPS and PGN. Interestingly, our results prove that
cell debris co-purifiedwith IBs (all of them produced under the same growth conditions), and
more specifically total lipid content, largely depends on the genetic background of the
Fig 8. Analysis of gene expression in RT-HKM cells stimulated with iRFP-H6 (BL21(DE3)) IBs and LPS.
Cells were incubated with 10 μg/ml of iRFP-H6 (BL21(DE3)) IBs and 10 μg/ml LPS for 12 h and the gene
expression was analyzed by qPCR. Values represent means ± SD (n = 3). Significant differences against control
were analyzed using One-way ANOVA followed by Tukey’s post test; *, p<0.05; **, p<0.01; ***, p<0.001.
doi:10.1371/journal.pone.0164073.g008
Biomaterials as Immunostimulants
PLOS ONE | DOI:10.1371/journal.pone.0164073 October 7, 2016 13 / 17
producing cells (Fig 2A). As it has been describedpreviously, the genetic background of the
producing strain, as well as the nature of the recombinant protein used to generated IBs, have
also a significant impact on the final IB shape and size (Fig 1) [27, 28]. Such compositional
complexity combined in a single particle with a structured form, two properties that can be eas-
ily modulated, is what makes IBs appealing as immunostimulators to enhance the immune
protection. Here, we provide evidence that heterologous IBs can be used to protect zebrafish
against otherwise lethal bacterial challenge (Figs 5–7). Our results suggest that none of the indi-
vidual components embedded in IBs such as LPS, lipid or the recombinant protein itself, is
solely responsible for induction of immune protection, but the combination of all of them in
an organized and stable structuredmaterial (Figs 6 and 7). IBs are not a simple mixture of pro-
tein, LPS and other bacterial cell wall components, but protein aggregates perfectly structured
forming a well-defined and resistant protein scaffold where different components are embed-
ded, providing stability and slow release liberation to all of them [21, 29]. This novel combina-
tion of properties provides a different form of immunostimulant from a mere mix of protein,
LPS and other bacterial components.
It is important to note that the use of different E. coli strains allow us to design IBs with eas-
ily modulated composition. However, we can affirm that the protective effect of the IBs in fish
is independent of the LPS chemotype of the production strain (Fig 6), which means that LPS
activity is not the only responsible of the protection observed.Besides, the different lipid con-
tent (Fig 2A) does not explain the slightly higher protection levels observedupon administra-
tion of VP1GFP (KPM335) IBs materials (Fig 6). Finally, the absence of significant differences
between the immunoprotective capacities of these biomaterials form by two different aminoa-
cidic sequences suggested that the nature of the protein itself does not have any effect on pro-
tection (Fig 7).
Regarding the proteins used for IB formation in this study, both model proteins are fluores-
cent reporters with no extra function known in fish. Nevertheless, it cannot be ruled out that, if
using IBs with a specific fish protein involved in immune response (e.g. cytokines), even higher
protection levels could be achieved, thus opening a new door to further tune the immunosti-
mulant capacity of the biomaterial.
Finally, IBs have an intrinsic capacity to be efficiently endocyted in both zebrafish cells and
trout macrophages. The intracellular accumulation of the structured biomaterial has already
been studied in detail using a human cell line and, in general terms, the localization observed
in fish cell lines (Figs 3 and 4) is perfectly consistent with the mechanism proposed in mamma-
lian cell lines [21]. Briefly, IBs, after being intimately attached to the cell membrane, are inter-
nalized following a macropinocytic pathway [21], reaching maximum levels at 24 h (Figs 3 and
4). This could be crucial considering the localization of the TLRs involved in bacterial DNA
recognition (TLR9) in endosomal compartments. The capacity of IBs to target these intracellu-
lar receptors, which recognize specific unmethylated CpG motifs prevalent in microbial but
not in vertebrate genomic DNA, could lead to the activation of the TLR9 signaling pathways
that ends up with the synthesis of several cytokines. In agreement with this, we observed an
increase of gene expression of several markers involved in inflammation in primary cultures of
trout such as TNF-α, COX-2, IL-1-β, IL-8 or MMP9, all of them being crucial for the fish
immune response (Fig 8). This increase is probably a combined effect of the activation of differ-
ent TLRs, including those located in the endosomalmembrane such as TLR9.
Conclusions
The results obtained in this work allow us to propose IBs as a promising alternative immunos-
timulant to be used in intensive aquaculture. IBs are highly stable protein-based biomaterials
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obtained under recombinant production conditions able to provide good protection levels for
zebrafish against a lethal bacterial challenge. Their inherent nature makes them exceptionally
interesting, since the components embedded in a single particle allow them to increase innate
fish immune protection. Moreover, IBs, in contrast to synthetic biomaterials, are natural cell
components that can be easily produced by biofabrication in a cost-effectivemanner using
recombinant bacteria as cell factories. This means that their production can be easily scaled up,
becoming attractive for veterinary purposes. Besides, this study can potentially open a new
field of study to take a step forward in the evaluation of this excellent biomaterial as adjuvants
for vaccination purposes.
Supporting Information
S1 Fig. Toxicity in ZFL cell cultures after 24 h incubation with VP1GFP (ClpA-) IBs. Rela-
tive cell number of ZFL cells after the incubation with 0.1, 1 and 10 μg of VP1GFP (ClpA-) IBs
in 96 well plates during 24 h. Control cells without IBs indicates 100% of cell viability.
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